Jyong Biotech Ltd.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsJyong Biotech Ltd. is a Cayman Islands-incorporated, Nasdaq-listed pharmaceutical preparations company based in New Taipei City, Taiwan, with no revenue disclosed in the provided excerpts.
What they do
Jyong Biotech Ltd. is a pharmaceutical preparations company incorporated in the Cayman Islands and headquartered in New Taipei City, Taiwan. It operates through subsidiaries and is listed on the Nasdaq Stock Market under the symbol MENS. The provided filing excerpts do not describe its specific products, pipeline, or customer base.
Revenue drivers
- Not disclosed — The excerpts provided contain no product, segment, or revenue information.
Recent performance
For fiscal year 2025, the company reported a net loss of $4.7 million, compared with net losses of $3.0 million in 2024 and $4.4 million in 2023. Diluted loss per share was $0.06 in 2025, $0.04 in 2024, and $0.06 in 2023. Operating cash flow was negative $3.0 million in 2025, negative $3.6 million in 2024, and negative $2.6 million in 2023. At December 31, 2025, total assets were $20.8 million, total liabilities were $45.7 million, and shareholders' equity was negative $24.9 million. Cash and equivalents stood at $1.2 million with long-term debt of $2.1 million.
Strategy
No strategy, investment, or priority details are present in the provided excerpts. The company is a Cayman Islands holding company with operations in Taiwan, which may affect its corporate and tax structure. The 20-F was filed for the fiscal year ended December 31, 2025.
Risks
- Going concern — Negative shareholders' equity of $24.9 million and $1.2 million of cash against $45.7 million of liabilities as of December 31, 2025 raise going-concern concerns.
- Cash burn — Operating cash flow has been negative for three consecutive years, totaling approximately $9.2 million over 2023–2025.
- Losses — The company has reported annual net losses in each of 2023, 2024, and 2025, with a $4.7 million loss in 2025.
- Foreign private issuer — As a Cayman Islands company headquartered in Taiwan, the company is a foreign private issuer and its disclosure obligations may differ from those of U.S. domestic issuers.
Outlook
Management's outlook is not described in the excerpts provided. The company reported no revenue information and continues to incur operating losses.